Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

Transthyretin amyloid cardiomyopathy (ATTR-CM) is an under-recognized cause of heart
failure (HF) in older adults, resulting from myocardial deposition of misfolded transthyretin …

Cardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the
deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the …

Cardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the
deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the …

Cardiomyopathy is a manifestation of transthyretin amyloidosis (ATTR), which is an
underrecognized systemic disease whereby the transthyretin protein misfolds to form fibrils …

Sharmila Dorbala, MD, MPH, FASNC, Chair*; Yukio Ando, MD, PhD†; Sabahat Bokhari,
MD‡; Angela Dispenzieri, MD § ; Rodney H. Falk, MD*; Victor A. Ferrari, MD∥; Marianna …

Background: Hereditary transthyretin-mediated (hATTR) amyloidosis is a rapidly
progressive, multisystem disease that presents with cardiomyopathy or polyneuropathy. The …

Aims Transthyretin cardiac amyloidosis (ATTR-CA) has been reported in patients with aortic
stenosis (AS) but its prevalence and phenotype are not known. We examine elderly patients …

Advances in cardiac imaging have resulted in greater recognition of cardiac amyloidosis in
everyday clinical practice, but the diagnosis continues to be made in patients with late-stage …

Cardiac amyloidosis (CA) is one of the most rapidly progressive forms of heart disease, with
a median survival from diagnosis, if untreated, ranging from< 6 months for light chain …